ClinicalTrials.gg

Program

CLDN6 CAR-T

Its studies are mostly in Testicular Neoplasms · Testicular Germ Cell Tumor, led by BioNTech.

Furthest: phase 2, since Apr 16, 20252 company-led studies, 1 open or runningNext primary completion: Aug 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech21 open or runningphase 2since Apr 16, 2025Jul 28, 2020Aug 2028phase 1 · NCT04503278

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2020First study: phase 1 study in Testicular NeoplasmsFirst studyNCT04503278 · 214 enrolled · Australia, Germany, Netherlands and more
  2. Apr 16, 2025Phase 2 study in Testicular Germ Cell TumorNCT06940804

Ahead

  1. Aug 2028Primary completion: phase 1 study in Testicular NeoplasmsNCT04503278

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06940804Testicular Germ Cell Tumor2WithdrawnJun 20420
NCT04503278Testicular Neoplasms · Australia, Germany, Netherlands and more1Active, not recruitingAug 2028214

How it is read

Names in the registry

  • “CLDN6 CAR-T”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.